Table 1.

Development of clinical trials of CAR-T cell therapy

	Methods of study and Indication of treatment	Study	Product	CAR-T infused/total number of patients	ORR/CR at day 90 (%)	Grade > 2 CRS/neurotoxicity (%)
r/r HBCL	Phase II More than ( >) 2 lines of chemotherapy	JULIET [9]	Tisagenlecleucel (Kymriah™)	115/238	53/40	22/12
	Phase II > 2 lines	ZUMA-1 [10]	Axicabtagene ciloleucel (Yescarta™)	101/111	83/58	13/31
	Phase II > 2 lines	TRANSCEND [11]	Lisocabtagene maraleucel (Breyanzi™)	269/344	73/53	2/10
	Phase III > 1 line with HSCT	BELINDA [12]	Tisagenlecleucel (Kymriah™)	155/322	46/28	5/2
	Phase III > 1 line with HSCT	ZUMA-7 [13]	Axicabtagene ciloleucel (Yescarta™)	170/359	83/65	6/21
	Phase III > 1 line with HSCT	TRANSFORM [14]	Lisocabtagene maraleucel (Breyanzi™)	184/232	86/66	1/4
	Phase II > 1 line without HSCT	ALYCANTE [15]	Axicabtagene ciloleucel (Yescarta™)	62/69	69/66	8/14
	Phase II > 1 line without HSCT	PILOT [16]	Lisocabtagene maraleucel (Breyanzi™)	61/74	80/54	1,5/5
r/r MCL	Phase II > 2 lines	ZUMA-2 [17]	Brexucabtagene autoleucel (Tecartus™)	68/74	91/68	15/31
r/r IBCL	Phase II > 2 lines	ELARA [18]	Tisagenlecleucel (Kymriah™)	97/119	86/68	0/3
	Phase II > 2 lines	ZUMA-5 [19]	Axicabtagene ciloleucel (Yescarta™)	148/153	94/77	7/19
r/r B-ALL	Phase II	ZUMA-3 [20]	Brexucabtagene autoleucel (Tecartus™)	55/71	71/56	24/25
r/r MM	Phase II > 2 lines	CARTITUDE-1 [21]	Ciltacabtagene autoleucel (Carvykti™)	97/113	98/82	4/2
	Phase III > 2 lines	KarMMa-3 [23]	Idecabtagene Vicleucel (Abecma™)	225/386	71/39	5/3

r/r relapsed/refractory, HBCL high-grade B cell lymphoma, MCL mantle cell lymphoma, IBCL indolent B cell lymphoma, B-ALL B cell acute lymphoblastic leukaemia, MM multiple myeloma, HSCT haematopoietic stem cell transplantation, ORR overall response rate, CR complete response rate, CRS cytokine release syndrome